FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300552654> ?p ?o ?g. }

• W4300552654 endingPage "113S" @default.
• W4300552654 startingPage "108S" @default.
• W4300552654 abstract "In a multicenter, double-blind, prospective, randomized, comparative study, fleroxacin, 400 mg once daily orally, was compared with norfloxacin, 400 mg twice daily orally. Each drug was given for 10 days to study efficacy and safety in the treatment of uncomplicated, recurrent, or complicated urinary tract infection (UTI). A total of 587 patients from 22 centers were enrolled and randomly assigned to fleroxacin (n = 291) or norfloxacin (n = 296). Of these, 163 patients in each group were included in the efficacy analysis, and 287 in the fleroxacin group and 292 in the norfloxacin group were included in the safety analysis. There was no difference between the two groups in terms of bacteriologic or clinical efficacy, with cure rates for each diagnostic subgroup of 93–100% in the fleroxacin group and 91–96% in the norfloxacin group. Superinfection, reinfection, or relapse, as well as development of resistance to the administered drugs, were infrequent and comparable in the two groups. Adverse events were documented in a significantly higher number of patients treated with fleroxacin and involved mainly the digestive system, the central nervous system, and the skin. However, >90% of such adverse events were judged as mild or moderate in severity and did not lead to premature termination of treatment. Fleroxacin exhibited a clinical and bacteriologic efficacy comparable to that of norfloxacin in this group of patients, with cure rates similar to those of other 4-quinolones, suggesting a promising role for fleroxacin in the treatment of both uncomplicated and complicated UTIs. However, the higher incidence of adverse events with fleroxacin warrants further investigation with special focus on adverse reactions. In a multicenter, double-blind, prospective, randomized, comparative study, fleroxacin, 400 mg once daily orally, was compared with norfloxacin, 400 mg twice daily orally. Each drug was given for 10 days to study efficacy and safety in the treatment of uncomplicated, recurrent, or complicated urinary tract infection (UTI). A total of 587 patients from 22 centers were enrolled and randomly assigned to fleroxacin (n = 291) or norfloxacin (n = 296). Of these, 163 patients in each group were included in the efficacy analysis, and 287 in the fleroxacin group and 292 in the norfloxacin group were included in the safety analysis. There was no difference between the two groups in terms of bacteriologic or clinical efficacy, with cure rates for each diagnostic subgroup of 93–100% in the fleroxacin group and 91–96% in the norfloxacin group. Superinfection, reinfection, or relapse, as well as development of resistance to the administered drugs, were infrequent and comparable in the two groups. Adverse events were documented in a significantly higher number of patients treated with fleroxacin and involved mainly the digestive system, the central nervous system, and the skin. However, >90% of such adverse events were judged as mild or moderate in severity and did not lead to premature termination of treatment. Fleroxacin exhibited a clinical and bacteriologic efficacy comparable to that of norfloxacin in this group of patients, with cure rates similar to those of other 4-quinolones, suggesting a promising role for fleroxacin in the treatment of both uncomplicated and complicated UTIs. However, the higher incidence of adverse events with fleroxacin warrants further investigation with special focus on adverse reactions." @default.
• W4300552654 created "2022-10-03" @default.
• W4300552654 creator A5036492260 @default.
• W4300552654 date "1993-03-01" @default.
• W4300552654 modified "2023-10-17" @default.
• W4300552654 title "Fleroxacin Versus Norfloxacin in the Treatment of Urinary Tract Infections: A Multicenter, Double-Blind, Prospective, Randomized, Comparative Study" @default.
• W4300552654 cites W1966138471 @default.
• W4300552654 cites W1981696724 @default.
• W4300552654 cites W1989280559 @default.
• W4300552654 cites W2006109029 @default.
• W4300552654 cites W2056192629 @default.
• W4300552654 cites W2126642299 @default.
• W4300552654 cites W2130380765 @default.
• W4300552654 cites W2171669224 @default.
• W4300552654 doi "https://doi.org/10.1016/s0002-9343(20)31149-9" @default.
• W4300552654 hasPublicationYear "1993" @default.
• W4300552654 type Work @default.
• W4300552654 citedByCount "7" @default.
• W4300552654 crossrefType "journal-article" @default.
• W4300552654 hasAuthorship W4300552654A5036492260 @default.
• W4300552654 hasConcept C126322002 @default.
• W4300552654 hasConcept C141071460 @default.
• W4300552654 hasConcept C168563851 @default.
• W4300552654 hasConcept C188816634 @default.
• W4300552654 hasConcept C197934379 @default.
• W4300552654 hasConcept C2777316974 @default.
• W4300552654 hasConcept C2778049240 @default.
• W4300552654 hasConcept C2778512257 @default.
• W4300552654 hasConcept C2778746504 @default.
• W4300552654 hasConcept C3019249092 @default.
• W4300552654 hasConcept C501593827 @default.
• W4300552654 hasConcept C71924100 @default.
• W4300552654 hasConcept C77411442 @default.
• W4300552654 hasConcept C86803240 @default.
• W4300552654 hasConcept C89423630 @default.
• W4300552654 hasConcept C90924648 @default.
• W4300552654 hasConceptScore W4300552654C126322002 @default.
• W4300552654 hasConceptScore W4300552654C141071460 @default.
• W4300552654 hasConceptScore W4300552654C168563851 @default.
• W4300552654 hasConceptScore W4300552654C188816634 @default.
• W4300552654 hasConceptScore W4300552654C197934379 @default.
• W4300552654 hasConceptScore W4300552654C2777316974 @default.
• W4300552654 hasConceptScore W4300552654C2778049240 @default.
• W4300552654 hasConceptScore W4300552654C2778512257 @default.
• W4300552654 hasConceptScore W4300552654C2778746504 @default.
• W4300552654 hasConceptScore W4300552654C3019249092 @default.
• W4300552654 hasConceptScore W4300552654C501593827 @default.
• W4300552654 hasConceptScore W4300552654C71924100 @default.
• W4300552654 hasConceptScore W4300552654C77411442 @default.
• W4300552654 hasConceptScore W4300552654C86803240 @default.
• W4300552654 hasConceptScore W4300552654C89423630 @default.
• W4300552654 hasConceptScore W4300552654C90924648 @default.
• W4300552654 hasIssue "3" @default.
• W4300552654 hasLocation W43005526541 @default.
• W4300552654 hasOpenAccess W4300552654 @default.
• W4300552654 hasPrimaryLocation W43005526541 @default.
• W4300552654 hasRelatedWork W1931884970 @default.
• W4300552654 hasRelatedWork W1970455542 @default.
• W4300552654 hasRelatedWork W2001616571 @default.
• W4300552654 hasRelatedWork W2023570856 @default.
• W4300552654 hasRelatedWork W2035666403 @default.
• W4300552654 hasRelatedWork W207222497 @default.
• W4300552654 hasRelatedWork W2262765979 @default.
• W4300552654 hasRelatedWork W2364762990 @default.
• W4300552654 hasRelatedWork W2411666713 @default.
• W4300552654 hasRelatedWork W94564799 @default.
• W4300552654 hasVolume "94" @default.
• W4300552654 isParatext "false" @default.
• W4300552654 isRetracted "false" @default.
• W4300552654 workType "article" @default.